TAVEGIL

This brand name is authorized in Germany, Estonia, United Kingdom

Active ingredients

The drug TAVEGIL contains one active pharmaceutical ingredient (API):

1 Clemastine
UNII 19259EGQ3D - CLEMASTINE FUMARATE

Clemastine is an H1-receptor antagonist. It inhibits selectively the histamine receptors of the H1 type and reduces capillary permeability. It exerts a potent antihistaminic and antipruritic effect with a fast onset and long duration of action.

Read about Clemastine

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
TAVEGIL Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
R06AA04 Clemastine R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AA Aminoalkyl ethers
Discover more medicines within R06AA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: DE Bundesinstitut fĂźr Arzneimittel und Medizinprodukte Identifier(s): 01006571, 01407666, 03052138, 03052144, 03257662, 03257679, 04965993, 04966001
Country: EE Ravimiamet Identifier(s): 1800403
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 36504

Š All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈